JP2020535167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535167A5 JP2020535167A5 JP2020517489A JP2020517489A JP2020535167A5 JP 2020535167 A5 JP2020535167 A5 JP 2020535167A5 JP 2020517489 A JP2020517489 A JP 2020517489A JP 2020517489 A JP2020517489 A JP 2020517489A JP 2020535167 A5 JP2020535167 A5 JP 2020535167A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- alanine
- headache
- antibody
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021157701A JP7221352B2 (ja) | 2017-09-29 | 2021-09-28 | 抗ｐａｃａｐ抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565278P | 2017-09-29 | 2017-09-29 | |
| US62/565,278 | 2017-09-29 | ||
| PCT/US2018/051898 WO2019067293A1 (en) | 2017-09-29 | 2018-09-20 | ANTI-PACAP ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021157701A Division JP7221352B2 (ja) | 2017-09-29 | 2021-09-28 | 抗ｐａｃａｐ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535167A JP2020535167A (ja) | 2020-12-03 |
| JP2020535167A5 true JP2020535167A5 (https=) | 2021-01-21 |
| JP6952888B2 JP6952888B2 (ja) | 2021-10-27 |
Family
ID=63794713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517489A Active JP6952888B2 (ja) | 2017-09-29 | 2018-09-20 | 抗ｐａｃａｐ抗体 |
| JP2021157701A Active JP7221352B2 (ja) | 2017-09-29 | 2021-09-28 | 抗ｐａｃａｐ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021157701A Active JP7221352B2 (ja) | 2017-09-29 | 2021-09-28 | 抗ｐａｃａｐ抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10519225B2 (https=) |
| EP (1) | EP3688035A1 (https=) |
| JP (2) | JP6952888B2 (https=) |
| KR (1) | KR102453573B1 (https=) |
| CN (1) | CN111164105B (https=) |
| AR (1) | AR113022A1 (https=) |
| AU (1) | AU2018341959B2 (https=) |
| BR (1) | BR112020003628A2 (https=) |
| CA (1) | CA3077304C (https=) |
| CL (1) | CL2020000705A1 (https=) |
| CO (1) | CO2020002170A2 (https=) |
| CR (1) | CR20200127A (https=) |
| DO (1) | DOP2020000060A (https=) |
| EA (1) | EA202090563A1 (https=) |
| EC (1) | ECSP20020293A (https=) |
| IL (1) | IL273529A (https=) |
| JO (1) | JOP20200069A1 (https=) |
| MA (1) | MA50654A (https=) |
| MX (1) | MX2020003563A (https=) |
| MY (1) | MY199876A (https=) |
| NZ (1) | NZ762312A (https=) |
| PE (1) | PE20201494A1 (https=) |
| PH (1) | PH12020550340A1 (https=) |
| SG (1) | SG11202002572YA (https=) |
| TW (1) | TWI701260B (https=) |
| WO (1) | WO2019067293A1 (https=) |
| ZA (1) | ZA202001058B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2982861A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| EP3426288A4 (en) | 2016-04-15 | 2019-10-30 | Alder Biopharmaceuticals, Inc. | ANTI-PACAP ANTIBODIES AND USES THEREOF |
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| WO2023010065A2 (en) * | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| CN117916259A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cgrp和pacap的抗原结合分子及其医药用途 |
| KR102839881B1 (ko) * | 2021-11-19 | 2025-07-31 | 대한민국 | 방송통신기자재 성능 측정 시스템 및 그 방법 |
| WO2024218541A1 (en) * | 2023-04-20 | 2024-10-24 | Mark Hasleton | Treatment of migraine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486472A (en) | 1990-03-17 | 1996-01-23 | Takeda Chemical Industries, Ltd. | Monoclonal antibodies to PACAP |
| US6037321A (en) | 1995-05-03 | 2000-03-14 | Biostar Inc. | Fusion proteins comprising vasoactive intestinal peptide or PACAP |
| FR2826747B1 (fr) | 2001-07-02 | 2005-02-25 | Gemplus Card Int | Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce |
| US7615219B2 (en) | 2003-01-16 | 2009-11-10 | Life Sciences Research Partners Vzw | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
| WO2012106407A2 (en) | 2011-02-01 | 2012-08-09 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
| JP6064861B2 (ja) | 2013-03-05 | 2017-01-25 | 株式会社デンソー | 熱電変換装置の製造方法 |
| CA2906737C (en) * | 2013-03-15 | 2023-08-15 | Amgen Inc. | Human pac1 antibodies |
| EP3035950A4 (en) | 2013-08-14 | 2017-05-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
| CA2982861A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| US10822408B2 (en) * | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
| WO2017142961A1 (en) | 2016-02-16 | 2017-08-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Treatment of traumatic brain injury or stroke |
-
2018
- 2018-09-13 AR ARP180102618A patent/AR113022A1/es not_active Application Discontinuation
- 2018-09-14 TW TW107132467A patent/TWI701260B/zh active
- 2018-09-20 MA MA050654A patent/MA50654A/fr unknown
- 2018-09-20 KR KR1020207008789A patent/KR102453573B1/ko active Active
- 2018-09-20 CA CA3077304A patent/CA3077304C/en active Active
- 2018-09-20 CN CN201880063106.2A patent/CN111164105B/zh active Active
- 2018-09-20 SG SG11202002572YA patent/SG11202002572YA/en unknown
- 2018-09-20 WO PCT/US2018/051898 patent/WO2019067293A1/en not_active Ceased
- 2018-09-20 EA EA202090563A patent/EA202090563A1/ru unknown
- 2018-09-20 BR BR112020003628-5A patent/BR112020003628A2/pt not_active Application Discontinuation
- 2018-09-20 NZ NZ762312A patent/NZ762312A/en not_active IP Right Cessation
- 2018-09-20 MY MYPI2020001596A patent/MY199876A/en unknown
- 2018-09-20 JO JOP/2020/0069A patent/JOP20200069A1/ar unknown
- 2018-09-20 CR CR20200127A patent/CR20200127A/es unknown
- 2018-09-20 US US16/136,490 patent/US10519225B2/en active Active
- 2018-09-20 EP EP18783282.9A patent/EP3688035A1/en active Pending
- 2018-09-20 JP JP2020517489A patent/JP6952888B2/ja active Active
- 2018-09-20 PE PE2020000375A patent/PE20201494A1/es unknown
- 2018-09-20 AU AU2018341959A patent/AU2018341959B2/en not_active Ceased
- 2018-09-20 PH PH1/2020/550340A patent/PH12020550340A1/en unknown
- 2018-09-20 MX MX2020003563A patent/MX2020003563A/es unknown
-
2019
- 2019-11-22 US US16/692,236 patent/US10954292B2/en active Active
-
2020
- 2020-02-19 ZA ZA2020/01058A patent/ZA202001058B/en unknown
- 2020-02-27 CO CONC2020/0002170A patent/CO2020002170A2/es unknown
- 2020-03-16 DO DO2020000060A patent/DOP2020000060A/es unknown
- 2020-03-18 CL CL2020000705A patent/CL2020000705A1/es unknown
- 2020-03-23 IL IL273529A patent/IL273529A/en unknown
- 2020-03-26 EC ECSENADI202020293A patent/ECSP20020293A/es unknown
-
2021
- 2021-02-15 US US17/175,870 patent/US20210171616A1/en not_active Abandoned
- 2021-09-28 JP JP2021157701A patent/JP7221352B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535167A5 (https=) | ||
| JP2015514110A5 (https=) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2021529557A5 (https=) | ||
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| JP2013542194A5 (https=) | ||
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| JP2017505125A5 (https=) | ||
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| JP2020500538A5 (https=) | ||
| JP2015535828A5 (https=) | ||
| JP2019531764A5 (https=) | ||
| JP2025131696A5 (https=) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| JP2023093753A5 (https=) | ||
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| JP2021502984A5 (https=) |